Completed PHASE2 INTERVENTIONAL 4-arm NCT01440374

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (ASPIRE)

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)

Sponsor: Novartis Pharmaceuticals

Conditions Thrombocytopaenia

Interventions eltrombopag placebo

Updated 9 times since 2017 Last updated: May 2, 2017 Started: Sep 30, 2011 Primary completion: Mar 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01440374, this PHASE2 trial focuses on Thrombocytopaenia and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 9 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jul 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Jul 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Amsterdam, Netherlands , Antwerp, Belgium , Athens, Greece , Augusta, United States , Baltimore, United States , Bangkok, Thailand , Barcelona, Spain , Barretos, Brazil , Beersheba, Israel and 98 more locations